ECM
DSGN icon

ExodusPoint Capital Management’s Design Therapeutics DSGN Stock Holding History

ExodusPoint Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-265,384
Closed -$1.67M – 1794
2023
Q2 		$1.67M Buy
265,384
+109,246
+70% +$669K 0.01% 884
2023
Q1 		$901K Buy
156,138
+105,407
+208% +$788K 0.01% 1175
2022
Q4 		$521K Sell
50,731
-1,110
-2% -$15K 0.01% 1158
2022
Q3 		$867K Buy
+51,841
New +$1.03M 0.01% 1164

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ExodusPoint Capital Management's DSGN Position: Q3 2023 in Review

ExodusPoint Capital Management sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 265,384 shares — an estimated $1.67M sold.

ExodusPoint Capital Management first reported a position in DSGN in Q3 2022 and held it in 4 quarters. The position peaked at $1.67M in Q2 2023. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • ExodusPoint Capital Management reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • ExodusPoint Capital Management sold 265,384 Design Therapeutics shares in Q3 2023, an estimated $1.67M.
  • ExodusPoint Capital Management first reported a position in Design Therapeutics in Q3 2022 and held it in 4 quarters.
  • ExodusPoint Capital Management's Design Therapeutics position peaked at $1.67M in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.